Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-RAS-20001 of olomorasib in KRAS G12C-mutant advanced solid tumors
2022-502756-31-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of olomorasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-limiting toxicity rate and DLT-equivalent toxicities, Safety and tolerability and 1 more. Planned start Jul 2022; status: authorised.
02
Drugs
olomorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2022-502756-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502756-31-00.